Nektar Therapeutics

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 20,500 shares of its common stock and 3,900 restricted stock units (RSUs) to seven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).

prnewswire.com - 2026-06-26 16:30:00

Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted average price of $60.75 per share. This sale represented 26.64% of his direct common stock holdings and reduced his direct position from 75,073 to 55,045 shares.

fool.com - 2026-06-24 15:39:19

Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?

247wallst.com - 2026-06-23 07:55:41

SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common stock to five newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).

prnewswire.com - 2026-06-03 16:15:00

SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m.

prnewswire.com - 2026-05-27 18:15:00

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.

fool.com - 2026-05-16 10:09:15

Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial results and providing updates across its pipeline during its earnings call. Get Nektar Therapeutics alerts:Sign UpREZPEG positioned for phase III in atopic dermatitis President and CEO Howard Robin said the company is “exceptionally proud” of progress over the past year and highlighted phase IIb results in atopic dermatitis and alopecia areata that he said demonstrate clinically meaningful outcomes in two “distinct autoimmune and inflammatory disease settings.

marketbeat.com - 2026-05-08 16:09:38

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.

zacks.com - 2026-05-08 13:56:19

Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 05:11:18

SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31, 2025.

prnewswire.com - 2026-05-07 16:15:00

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-01951, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nektar securities between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

prnewswire.com - 2026-05-07 10:00:00

New York, New York--(Newsfile Corp. - May 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-05-05 21:27:00

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and certain officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-01951, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nektar securities between February 26, 2025 and December 15, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

globenewswire.com - 2026-05-05 16:29:00

LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”).

globenewswire.com - 2026-05-05 13:12:00

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nektar securities between February 26, 2025 and December 25, 2025, both dates inclusive (the “Class Period”).

globenewswire.com - 2026-05-05 12:00:00

New York, New York--(Newsfile Corp. - May 5, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law

feeds.newsfilecorp.com - 2026-05-05 12:00:00

Nektar Therapeutics is significantly de-risked after positive Rezpeg phase 2 data in atopic dermatitis and alopecia areata, targeting multi-billion dollar markets. Rezpeg's strong safety profile, infrequent dosing, and potential first-line use in alopecia areata position and substantial market share in atopic dermatitis even without best-in-class efficacy. Probability-weighted outcomes have shifted materially positive post-AA readout, with over 80% upside to current prices and downside risk now sharply reduced.

seekingalpha.com - 2026-05-05 10:24:29

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 5, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

prnewswire.com - 2026-05-05 09:59:00

LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nektar Therapeutics, Inc., (“Nektar” or the "Company") (NASDAQ: NKTR) investors off a class action on behalf of investors that bought securities between February 26, 2026 and December 12, 2025, inclusive (the “Class Period”). Nektar investors have until May 5, 2026 to file a lead plaintiff motion.

globenewswire.com - 2026-05-05 09:00:00

NEW YORK, May 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

prnewswire.com - 2026-05-05 09:00:00

NEW YORK, May 4, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. So what: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

prnewswire.com - 2026-05-04 21:54:00

New York, New York--(Newsfile Corp. - May 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-05-04 21:22:00

Promise vs. Reality: The Nektar Therapeutics REZOLVE-AA Performance Gap Promise vs. Reality: The Nektar Therapeutics REZOLVE-AA Performance Gap

globenewswire.com - 2026-05-04 20:23:00

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Nektar (NKTR) To Contact Him Directly To Discuss Their Options

globenewswire.com - 2026-05-04 18:57:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

newsfilecorp.com - 2026-05-04 12:28:00

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEKTAR THERAPEUTICS (NKTR), CLICK HERE TO PARTICIPATE IN THE SE.

businesswire.com - 2026-05-04 12:00:00

LOS ANGELES, May 4, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

prnewswire.com - 2026-05-04 04:02:00

LOS ANGELES, May 4, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 26, 2025 and December 15, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 5, 2026.

prnewswire.com - 2026-05-04 04:01:00

NEW YORK, May 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.

globenewswire.com - 2026-05-03 21:38:00

New York, New York--(Newsfile Corp. - May 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-05-03 21:17:00

New York, New York--(Newsfile Corp. - May 3, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law

feeds.newsfilecorp.com - 2026-05-03 12:00:00

New York, New York--(Newsfile Corp. - May 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-05-02 21:43:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

newsfilecorp.com - 2026-05-02 08:07:00

New York, New York--(Newsfile Corp. - May 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-05-01 21:40:00

SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of its common stock and 2,950 restricted stock units (RSUs) to six newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).

prnewswire.com - 2026-05-01 16:39:00

New York, New York--(Newsfile Corp. - May 1, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law

feeds.newsfilecorp.com - 2026-05-01 12:00:00

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nektar securities between February 26, 2025 and December 25, 2025, both dates inclusive (the “Class Period”).

globenewswire.com - 2026-05-01 12:00:00

LOS ANGELES, May 1, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). IF YOU SUFFERED A LOSS ON YOUR NEKTAR INVESTMENTS, CLICK  HERE BEFORE MAY 5, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

prnewswire.com - 2026-05-01 12:00:00

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

globenewswire.com - 2026-05-01 09:00:00

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-01951, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nektar securities between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

prnewswire.com - 2026-04-30 20:40:00

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.

globenewswire.com - 2026-04-30 13:24:09

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline.

globenewswire.com - 2026-04-30 13:24:00

New York, New York--(Newsfile Corp. - April 30, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law

feeds.newsfilecorp.com - 2026-04-30 12:00:00

LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 26, 2025 and December 15, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before May 5, 2026.

globenewswire.com - 2026-04-30 10:31:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK, April 30, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

prnewswire.com - 2026-04-30 09:44:00

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join the Nektar Class Action Lawsuit?

globenewswire.com - 2026-04-30 09:33:00

Wall Street Reassessment: Analyst Opinion Evolution on NKTR NEW YORK, April 30, 2026 /PRNewswire/ -- At least seven major Wall Street firms issued reports on December 16, 2025, each flagging the same problem: four patients who never should have been randomized into Nektar Therapeutics' (NASDAQ: NKTR) pivotal REZOLVE-AA trial were included, and the trial's primary endpoint missed statistical significance as a result. Shareholders who purchased NKTR securities between February 26, 2025 and December 15, 2025 and suffered losses may be entitled to compensation.

prnewswire.com - 2026-04-30 09:00:00

New York, New York--(Newsfile Corp. - April 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-04-29 19:31:00

New York, New York--(Newsfile Corp. - April 29, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a

feeds.newsfilecorp.com - 2026-04-29 09:28:00

Executive Accountability: Jonathan Zalevsky Named in Securities Action NEW YORK, April 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors that Jonathan Zalevsky, Chief Research and Development Officer of Nektar Therapeutics (NASDAQ: NKTR), is named as an individual defendant in a securities class action filed on behalf of shareholders who purchased securities between February 26, 2025 and December 15, 2025. Find out if you can recover your investment losses.

prnewswire.com - 2026-04-29 09:00:00